Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
Nexalin Technology Inc. (NXL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: NXL (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $4
1 Year Target Price $4
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 45.18% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 14.63M USD | Price to earnings Ratio - | 1Y Target Price 4 |
Price to earnings Ratio - | 1Y Target Price 4 | ||
Volume (30-day avg) 1 | Beta 3.73 | 52 Weeks Range 0.59 - 4.49 | Updated Date 09/17/2025 |
52 Weeks Range 0.59 - 4.49 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.77 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-09-03 | When - | Estimate -0.14 | Actual -0.1 |
Profitability
Profit Margin - | Operating Margin (TTM) -2296.22% |
Management Effectiveness
Return on Assets (TTM) -138.67% | Return on Equity (TTM) -242.01% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 11687090 | Price to Sales(TTM) 83.7 |
Enterprise Value 11687090 | Price to Sales(TTM) 83.7 | ||
Enterprise Value to Revenue 66.85 | Enterprise Value to EBITDA 0.02 | Shares Outstanding 17417900 | Shares Floating 14895639 |
Shares Outstanding 17417900 | Shares Floating 14895639 | ||
Percent Insiders 14.34 | Percent Institutions 7.53 |
Upturn AI SWOT
Nexalin Technology Inc.
Company Overview
History and Background
Nexalin Technology, Inc. is a medical device company focused on developing and commercializing neurostimulation products to treat mental health disorders. Founded in 2010, the company has focused on treating anxiety, depression, and insomnia through non-invasive brain stimulation.
Core Business Areas
- Neurostimulation Therapy: Nexalin develops and markets medical devices that utilize a non-invasive brain stimulation technology to modulate neural activity and treat mental health disorders such as anxiety, depression, and insomnia.
- Product Development: Nexalin invests in research and development to create new neurostimulation devices and improve existing technologies to enhance their efficacy and expand their application to different conditions.
Leadership and Structure
Mark Swingle serves as the Chief Executive Officer of Nexalin Technology, Inc. The company has a board of directors and a management team overseeing various functions such as research and development, sales, and marketing.
Top Products and Market Share
Key Offerings
- Gen-1 and Gen-2 Neurostimulation Devices: These devices deliver a non-invasive brain stimulation therapy designed to treat anxiety, depression, and insomnia. The market is competitive with other neurostimulation technologies and pharmaceutical treatments. There is no exact market share data for each product as it is an emerging technology.
Market Dynamics
Industry Overview
The neurostimulation device market is growing, driven by increasing prevalence of mental health disorders and a growing preference for non-pharmacological treatments. The market includes TMS, tDCS, and VNS, offering various approaches to brain stimulation.
Positioning
Nexalin Technology, Inc. is positioned as a developer and marketer of non-invasive brain stimulation devices, emphasizing safety and efficacy in treating mental health conditions. They compete against established players in the neurostimulation space.
Total Addressable Market (TAM)
The global neurostimulation devices market is projected to reach billions of dollars. Nexalin is positioned to capture a portion of this TAM through focused treatment offerings for specific mental health indications.
Upturn SWOT Analysis
Strengths
- Non-invasive technology
- Targeted treatment for mental health disorders
- Potential for fewer side effects compared to medication
Weaknesses
- Limited clinical data compared to established treatments
- Market adoption challenges
- Dependence on regulatory approvals
Opportunities
- Expanding indications for neurostimulation therapy
- Partnerships with healthcare providers
- Growing awareness of mental health treatments
Threats
- Competition from established treatments (medication, TMS)
- Reimbursement challenges from insurance companies
- Technological advancements from competitors
Competitors and Market Share
Key Competitors
- ALKS
- STIM
- CERU
Competitive Landscape
Nexalin Technology faces competition from established pharmaceutical companies and other neurostimulation device manufacturers. They need to demonstrate superior efficacy and safety to gain market share.
Growth Trajectory and Initiatives
Historical Growth: Historical growth data will need to be gathered from official financial filings by Nexalin Technology.
Future Projections: Future projections will need to be gathered from analysts estimates from Nexalin Technology.
Recent Initiatives: Nexalin Technology is focused on expanding clinical trials and securing regulatory approvals for its devices.
Summary
Nexalin Technology is a small company in the neurostimulation space, targeting mental health disorders. Its non-invasive technology is a potential strength, but it faces challenges due to limited clinical data and competition from established treatments. Successful clinical trials and regulatory approvals are crucial for its future growth. It should closely monitor the development and adoption of other neurostimulation treatments.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
- Analyst Reports (where available)
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share estimates are approximate. Consult with a financial professional before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Nexalin Technology Inc.
Exchange NASDAQ | Headquaters Houston, TX, United States | ||
IPO Launch date 2022-09-16 | President, CEO & Director Mr. Mark White | ||
Sector Healthcare | Industry Medical Devices | Full time employees 6 | Website https://www.nexalin.com |
Full time employees 6 | Website https://www.nexalin.com | ||
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company offers Generation 1, an easy-to-administer medical device which utilizes bioelectronic medical technology to treat anxiety, insomnia, and depression without the need for drugs or psychotherapy; and Generation 2 and Generation 3 headset devices for the treatment of depression, substance use disorder, traumatic brain injury, post-traumatic stress disorder, opioid addiction, alcoholism, and chronic pain, as well as alzheimer's disease, and dementia. Nexalin Technology, Inc. is headquartered in Houston, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.